• Intelligent Bio Solutions posted fiscal 2026 revenue of $4.22 million, up 38% year-over-year.
• Gross profit more than doubled to $2.05 million; gross margin widened 7.78 percentage points to 48.63%.
• Operating loss widened to $12.61 million; net loss attributable to shareholders widened to $12.43 million.
• Reader installed base climbed 22% to 1,886 units; consumable cartridges rose 35% to 106,500 units.
• Completed clinical data collection for its FDA 510(k) program; submission remains on track for the second half of calendar 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190830PRIMZONEFULLFEED9812385) on August 19, 2026, and is solely responsible for the information contained therein.